IP strategy for AI and data-driven chemistry

With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk